Pegylated Interferon Alfa-2a and Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia: Differential Cellular and Molecular Responses

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2018 Mar 21

PMID 29556018

Citations 12

Authors

Tsewang Tashi

Sabina Swierczek

Soo Jin Kim

Mohamed E Salama

Jihyun Song

Nahla Heikal

Katherine Y King

Kim Hickman

Scott Litton

Josef T Prchal

Affiliations

Soon will be listed here.

Citing Articles

Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.

Qin A, Wu D, Liao J, Xie S, Chen H, Gao Y Front Pharmacol. 2024; 15:1455979.

PMID: 39386026 PMC: 11463156. DOI: 10.3389/fphar.2024.1455979.

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.

Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian J, Pemmaraju N Br J Haematol. 2024; 205(1):48-60.

PMID: 38853641 PMC: 11245372. DOI: 10.1111/bjh.19557.

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.

Qin A, Urbanski R, Yu L, Ahmed T, Mascarenhas J Front Oncol. 2023; 13:1109866.

PMID: 36776307 PMC: 9913265. DOI: 10.3389/fonc.2023.1109866.

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.

Hasselbalch H, Skov V, Kjaer L, Larsen M, Knudsen T, Lucijanic M Cancers (Basel). 2022; 14(22).

PMID: 36428587 PMC: 9688061. DOI: 10.3390/cancers14225495.

Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression.

Song J, Kim S, Gollamudi J, Thiagarajan P, Prchal J Blood Adv. 2022; 7(5):712-717.

PMID: 36343116 PMC: 9984957. DOI: 10.1182/bloodadvances.2022008052.

References

Liu E, Jelinek J, Pastore Y, Guan Y, Prchal J, Prchal J . Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003; 101(8):3294-301. DOI: 10.1182/blood-2002-07-2287. View

Nussenzveig R, Swierczek S, Jelinek J, Gaikwad A, Liu E, Verstovsek S . Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007; 35(1):32-8. DOI: 10.1016/j.exphem.2006.11.012. View

Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal J . In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol. 2007; 35(4):587-95. PMC: 1931508. DOI: 10.1016/j.exphem.2006.12.007. View

Kiladjian J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M . Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8):3065-72. DOI: 10.1182/blood-2008-03-143537. View

Moliterno A, Williams D, Rogers O, Isaacs M, Spivak J . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol. 2008; 36(11):1480-6. PMC: 2600434. DOI: 10.1016/j.exphem.2008.05.006. View

Bruchova H, Yoon D, Agarwal A, Swierczek S, Prchal J . Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009; 43(1):81-7. PMC: 2693444. DOI: 10.1016/j.bcmd.2009.02.001. View

Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S . Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32):5418-24. PMC: 4881362. DOI: 10.1200/JCO.2009.23.6075. View

Fleischman A, Aichberger K, Luty S, Bumm T, Petersen C, Doratotaj S . TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011; 118(24):6392-8. PMC: 3236121. DOI: 10.1182/blood-2011-04-348144. View

Hayes C, Imamura M, Aikata H, Chayama K . Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012; 9(7):406-17. DOI: 10.1038/nrgastro.2012.101. View

10.

Vaidya R, Gangat N, Jimma T, Finke C, Lasho T, Pardanani A . Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012; 87(11):1003-5. DOI: 10.1002/ajh.23295. View

11.

Klampfl T, Gisslinger H, Harutyunyan A, Nivarthi H, Rumi E, Milosevic J . Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369(25):2379-90. DOI: 10.1056/NEJMoa1311347. View

12.

Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P . Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014; 42(5):360-8. DOI: 10.1016/j.exphem.2014.01.006. View

13.

King K, Matatall K, Shen C, Goodell M, Swierczek S, Prchal J . Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol. 2015; 43(10):912-918.e2. PMC: 4592796. DOI: 10.1016/j.exphem.2015.05.013. View

14.

Chen Y, Zou Z, Wu Z, Zhao Z, Luo X, Xie C . TNF-α-induced programmed cell death in the pathogenesis of acquired aplastic anemia. Expert Rev Hematol. 2015; 8(4):515-26. DOI: 10.1586/17474086.2015.1049593. View